Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Issued (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Shares Issued data on record, last reported at -$14000.0 in Q3 2025.

  • For Q3 2025, Shares Issued changed N/A year-over-year to -$14000.0; the TTM value through Sep 2025 reached -$48.9 million, down 167.05%, while the annual FY2024 figure was $1.1 million, 95.76% down from the prior year.
  • Shares Issued reached -$14000.0 in Q3 2025 per GLUE's latest filing, down from $14000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $49.8 million in Q2 2024 and bottomed at -$48.9 million in Q4 2024.
  • Average Shares Issued over 3 years is $2.9 million, with a median of $18000.0 recorded in 2023.
  • The widest YoY moves for Shares Issued: up 276511.11% in 2024, down 312.93% in 2024.
  • A 3-year view of Shares Issued shows it stood at $23.0 million in 2023, then crashed by 312.93% to -$48.9 million in 2024, then surged by 99.97% to -$14000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$14000.0 in Q3 2025, $14000.0 in Q1 2025, and -$48.9 million in Q4 2024.